CANDIDIASIS

Feigin and Cherry's Textbook of Pediatric Infectious Diseases, Sixth Edition

Volumn , Issue , 2009, Pages 2741-2751

  Knapp, Katherine M ^a,b   Flynn, Patricia M ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952943572     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4044-6.50217-X     Document Type: Chapter

References (132)

1. J.A. Abelson, T. Moore, D. Bruckner, et al. (2005) Frequency of fungemia in hospitalized pediatric inpatients over 11 years at a tertiary care institution. Pediatrics 116 61-67.
2. B.S.P. Ang, A. Telenti, B. King, et al. (1993) Candidemia from a urinary tract source: Microbiological aspects and clinical significance. Clin. Infect. Dis. 17 662-666.
3. N.C. Austin and B. Darlow (2004) Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants. Cochrane Database Syst. Rev. 1 CD003478.
4. J.E. Baley, R.M. Kliegman and A.A. Faranoff (1984) Disseminated fungal infection in very low-birth-weight infants: Clinical manifestations and epidemiology. Pediatrics 73 144-152.
5. D.L. Bartley, W.T. Hughes, L.S. Parvey, et al. (1982) Computed tomography of hepatic and splenic fungal abscesses in leukemic children. Pediatr. Infect. Dis. 1 317-321.
6. A.S. Bayer, M.J. Blumenkrantz, J.Z. Montgomerie, et al. (1976) Candida peritonitis: Report of 22 cases and review of the English literature. Am. J. Med. 61 832-840.
7. D.K. Benjamin Jr., T. Driscoll, N.L. Seibel, et al. (2006) Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50 632-638.
8. D.K. Benjamin Jr., B.J. Stoll, A.A. Fanaroff, et al. (2006) Neonatal candidiasis among extremely low birth weight infants: Risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 117 84-92.
9. D.K. Benjamin Jr., C. Poole, W.J. Steinbach, et al. (2003) Neonatal candidemia and end-organ damage: A critical appraisal of the literature using meta-analytic techniques. Pediatrics 112 634-640.
10. D.K. Benjamin Jr., E.R. DeLong, W.J. Steinbach, et al. (2003) Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 112 543-547.
11. D.K. Benjamin Jr., K. Ross, D.K. Benjamin, et al. (2000) When to suspect fungal infections in neonates: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics 106 712-718.
12. P. Betremieux, S. Chevrier, G. Quindos, et al. (1994) Use of DNA fingerprinting and biotyping methods to study a Candida albicans outbreak in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 13 899-905.
13. R. Bowden, P. Chandrasekar, M.H. White, et al. (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35 359-366.
14. T.G. Buchman, M. Rossier, W.G. Merz and P. Charache (1990) Detection of surgical pathogens by in vitro DNA amplification. Part I. Rapid identification of Candida albicans by in vitro amplification of a fungus-specific gene. Surgery 108 338-346.
15. D.A. Caramalac, L. da Silva Ruiz, G.C.M. de Batista, et al. (2007) Candida isolated from vaginal mucosa of mothers and oral mucosa of neonates: Occurrence and biotypes concordance. Pediatr. Infect. Dis. J. 26 553-557.
16. O.A. Cornely, J. Maertens, D.J. Winston, et al. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356 348-359.
17. R.O. Darouiche, R.J. Hamill, D.M. Musher, et al. (1989) Periprosthetic candidal infections following arthroplasty. Rev. Infect. Dis. 11 89-96.
18. L. de Repentigny, F. Aumont, K. Bernard and P. Belhumeur (2000) Characterization of binding of Candida albicans to small intestinal mucin and its role in adherence to mucosal epithelial cells. Infect. Immun. 68 3172-3179.
19. R.D. Diamond, R. Krzesicki and J. Wellington (1978) Damage to pseudo hyphal forms of Candida albicans by neutrophils in the absence of serum in vitro. J. Clin. Invest. 61 349-359.
20. R.M. Donlon (2001) Biofilm formation: A clinically relevant microbiological process. Clin. Infect. Dis. 33 1387-1392.
21. S. Dreizen (1984) Oral candidiasis. Am. J. Med. 77 28-33.
22. J.E. Edwards, R.I. Lehrer, E.R. Stiehm, et al. (1978) Severe candidal infections: Clinical perspective, immune defense mechanisms, and current concepts of therapy. Am. J. Med. 89 91-106.
23. E.S. Eisenberg, I. Leviton and R. Soeiro (1986) Fungal peritonitis in patients receiving peritoneal dialysis: Experience with 11 patients and review of the literature. Rev. Infect. Dis. 8 309-321.
24. A.N.B. Ellepola and C.J. Morrison (2005) Laboratory diagnosis of invasive candidiasis. J. Microbiol. 43 65-84.
25. A.A. Fanaroff (2006) Fluconazole for the prevention of fungal infections: Get ready, get set, caution. Pediatrics 117 214-215.
26. P. Fan-Haward, C. O'Donovan, S.M. Smith, et al. (1995) Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin. Infect. Dis. 21 960-965.
27. J.F. Fisher (2000) Candiduria: When and how to treat it. Curr. Infect. Dis. Rep. 2 523-530.
28. J.F. Fisher, W.H. Chew, S. Shadomy, et al. (1982) Urinary tract infection due to Candida albicans. Rev. Infect. Dis. 4 1107-1118.
29. P.M. Flynn, C.K. Cunningham, T. Kerkering, et al. (1995) Oropharyngeal candidiasis in immunocompromised children: A randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J. Pediatr. 127 322-328.
30. P.M. Flynn, J.L. Shenep, R. Crawford and W.T. Hughes (1995) Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin. Infect. Dis. 20 964-970.
31. J.A. Franklin, J. McCormick and P.M. Flynn (2003) Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr. Infect. Dis. J. 22 747-749.
32. W.G. Franklin, A.B. Simon and T.M. Sodeman (1976) Candida myocarditis without valvulitis. Am. J. Cardiol. 38 924-928.
33. J. Garnacho-Montero, C. Ortiz-Leyba, J.L. Garcia Garmendia and F. Jimenez Jimenez (1998) Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate. Clin. Infect. Dis. 26 1016.
34. M.S. Gottlieb, R. Schroff, H.M. Schauber, et al. (1981) Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N. Engl. J. Med. 305 1425-1431.
35. D.K. Henderson, J.E. Edwards and J.Z. Montgomerie (1981) Hematogenous Candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J. Infect. Dis. 143 655-661.
36. D.K. Henderson, J.E. Edwards Jr., K. Ishida, et al. (1979) Experimental hematogenous Candida endophthalmitis diagnostic approaches. Infect. Immun. 23 858-862.
37. W.T. Hughes, D. Armstrong, G.P. Bodey, et al. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34 730-751.
38. W.T. Hughes, D.L. Bartley, G.G. Patterson, et al. (1983) Ketoconazole and candidiasis: A controlled study. J. Infect. Dis. 147 1060-1063.
39. W.T. Hughes (1982) Systemic candidiasis: A study of 109 fatal cases. Pediatr. Infect. Dis. 1 11-18.
40. W.T. Hughes (1971) Leukemia monitoring with fungal bone marrow cultures. J. A. M. A. 218 441-443.
41. B.J. Hurwich (1966) Monilial peritonitis. Arch. Intern. Med. 117 405.
42. M. Huttova, I. Hartmanova, K. Kralinsky, et al. (1998) Candida fungemia in neonates treated with fluconazole: Report of forty cases, including eight with meningitis. Pediatr. Infect. Dis. J. 17 1012-1015.
43. L.G. Jacobs, E.A. Skidmore, L.A. Cardoso and F. Ziv (1994) Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections. Clin. Infect. Dis. 18 313-318.
44. J. Kabe, Y. Aoki, T. Ishizaki, et al. (1971) Relationship of dermal and pulmonary sensitivity to extracts of Candida albicans. Am. Rev. Respir. Dis. 104 348-357.
45. C.A. Kauffman and S.W. Wiseman (1998) Anaphylaxis upon switching lipid-containing amphotericin B formulations. Clin. Infect. Dis. 26 1237-1238.
46. D. Kaufman, R. Boyle, K.C. Hazen, et al. (2001) Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. 345 1660-1666.
47. E.H. Kossoff, S. Buescher and M.G. Karlowicz (1998) Candidemia in a neonatal intensive care unit: Trends during 15 years and clinical features of 111 cases. Pediatr. Infect. Dis. J. 17 504-508.
48. P.J. Kozinn, C.L. Taschdjian and H. Wiener (1958) Incidence and pathogenesis of neonatal candidiasis. Pediatrics 21 421-429.
49. W. Krause, H. Matheis and K. Wulf (1969) Fungaemia and funguria after oral administration of Candida albicans. Lancet 1 598-599.
50. E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, et al. (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomized double-blind trial. Lancet 369 1519-1527.
51. R. Lawson, G. Bodey and M. Luna (1980) Case report: Candida infection presenting as laryngitis. Am. J. Med. Sci. 280 173-177.
52. R.I. Lehrer (1975) The fungicidal mechanisms of human monocytes. I. Evidence for myeloperoxidase-linked and myeloperoxidase-independent candidacidal mechanisms. J. Clin. Invest. 53 338-346.
53. R.I. Lehrer (1971) Measurement of candidacidal activity of specific leukocyte types in mixed cell populations II. Normal and chronic granulomatous disease eosinophils. Infect. Immun. 3 800-802.
54. J. Levine, R.K. Dykoski and E.N. Janoff (1995) Candida-associated diarrhea: A syndrome in search of credibility. Clin. Infect. Dis. 21 881-886.
55. I. Levy, L.G. Rubin, S. Vasishtha, et al. (1998) Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin. Infect. Dis. 26 1086-1088.
56. S.A. Lipton, W.F. Hickey, J.H. Morris, et al. (1984) Candidal infection in the central nervous system. Am. J. Med. 76 101-108.
57. L. MacDonald, C. Baker and C. Chenoweth (1998) Risk factors for candidemia in a children's hospital. Clin. Infect. Dis. 26 642-645.
58. I.R. Makhoul, I. Kassis, T. Smolkin, et al. (2001) Review of 49 neonates with acquired fungal sepsis: Further characterization. Pediatrics 107 61-66.
59. P. Manzoni, I. Stolfi, L. Pugni, et al., Italian Task Force for the Study and Prevention of Neonatal Fungal Infections and the Italian Society of Neonatology (2007) A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N. Engl. J. Med. 356 2483-2495.
60. P. Martino, C. Girmenia, A. Micozzi, et al. (1994) Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 13 797-804.
61. P. Martino, C. Girmenia, M. Vendetti, et al. (1989) Candida colonization and systemic infection in neutropenic patients: A retrospective study. Cancer 64 2030-2034.
62. L.T. Mathaba, A.E. Paxman, P.D. Ward, et al. (2000) Genetically distinct strains of Candida albicans with elevated secretory proteinase production are associated with diarrhoea in hospitalized children. J. Gastroenterol. Hepatol. 15 53-60.
63. J.A. McCullers, S. Vargas, P.M. Flynn, et al. (2000) Candidal meningitis in children with cancer. Clin. Infect. Dis. 31 451-457.
64. W. McGuire, L. Clerihew and N. Austin (2004) Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst. Rev. 1 CD003850.
65. R. McLeod and J.S. Remington (1977) Postoperative fungal endocarditis. R.J. Duma (Ed.) Infections of Prosthetic Heart Valves and Vascular Grafts: Prevention, Diagnosis and Treatment Baltimore: University Park Press 163.
66. G. Midgley and Y.M. Clayton (1972) Distribution of dermatophytes and Candida spores in the environment. Br. J. Dermatol. 86 69.
67. J.D. Milne and D.W. Warnock (1977) Antibodies to Candida albicans in human cervicovaginal secretions. Br. J. Vener. Dis. 53 375-378.
68. P. Mohan, O. Eddama and L.E. Weisman (2007) Patient isolation measures for infants with Candida colonization or infection for preventing or reducing transmission of Candida in neonatal units. Cochrane Database Syst. Rev. 3 CD006068.
69. L.F. Montes, R.F. Pittilo, D. Hunt, et al. (1971) Microbial flora of infant's skin. Arch. Dermatol. 103 400-406.
70. J.Z. Montgomerie and J.E. Edwards Jr. (1978) Association of infection due to Candida albicans with intravenous hyperalimentation. J. Infect. Dis. 137 197-201.
71. J. Mora-Duarte, R. Betts, C. Rotstein, et al. (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347 2020-2029.
72. C.J. Morrison, S.F. Hurst and E. Reiss (2003) Competitive binding inhibition enzyme-linked immunosorbent assay that uses the secreted aspartyl proteinase of Candida albicans as an antigenic marker for diagnosis of disseminated candidiasis. Clin. Diagn. Lab. Immunol. 10 835-848.
73. Multicentre Study Group (1988) Treatment of vaginal candidiasis with a single oral dose of fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 7 364-367.
74. B.K. Na and C.Y. Song (1999) Use of monoclonal antibody in diagnosis of candidiasis caused by Candida albicans: Detection of circulating aspartyl proteinase antigen. Clin. Diagn. Lab. Immunol. 6 924-929.
75. J.R. Naglik, C.A. Rodgers, P.J. Shirlaw, et al. (2003) Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. Clin. Infect. Dis. 188 469-479.
76. M.N. Neely and J.R. Schreiber (2001) Fluconazole prophylaxis in the very low birth weight infant: Not ready for prime time. Pediatrics 107 404-405.
77. J. Nett, L. Lincoln, K. Marchillo and D. Andes (2007) β-1,3 glucan as a test for central venous catheter biofilm infection. Clin. Infect. Dis. 195 1705-1712.
78. A.W.K. Ng, K.M. Wasan and G. Lopez-Berestein (2003) Development of liposomal polyene antibiotics: An historical perspective. J. Pharm. Pharm. Sci. 6 67-83.
79. M. Nucci and E. Anaissie (2002) Should vascular catheters be removed from all patients with candidemia?. An evidence-based review. Clin. Infect. Dis. 34 591-599.
80. M. Nucci, I. Biasoli, T. Akiti, et al. (2000) A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin. Infect. Dis. 30 300-305.
81. F.C. Odds (1979) Candida and Candidiasis Baltimore: University Park Press 382.
82. L. Ostrosky-Zeichner, B.D. Alexander, D.H. Kett, et al. (2005) Multicenter clinical evaluation of the (1→3) β- d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41 654-659.
83. P.G. Pappas, J.H. Rex, J.D. Sobel, et al. (2004) Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38 161-189.
84. P.G. Pappas, J.H. Rex, J. Lee, et al. (2003) A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37 634-643.
85. J.C. Parker, J.J. McClosky, K.V. Solanki, et al. (1976) Candidiasis: The most common postmortem cerebral mycosis in an endemic fungal area. Surg. Neurol. 6 123-128.
86. C.M. Perry, R. Whittington and D. McTavish (1995) Fluconazole: An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis. Drugs 49 984-1006.
87. M.A. Pfaller, D.J. Diekema, A.L. Colombo, et al. (2006) Candida rugosa, an emerging fungal pathogen with resistance to azoles: Geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol. 44 3578-3582.
88. M.A. Pfaller, D.J. Diekema, R.N. Jones, et al. (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40 852-856.
89. E. Piccolella, G. Lombardi and R. Morelli (1981) Generation of suppressor cells in the response of human lymphocytes to a polysaccharide from Candida albicans. J. Immunol. 126 2151-2155.
90. B. Piraino, G.R. Bailie, J. Bernardini, et al. (2005) Peritoneal dialysis–related infections recommendations: 2005 update. Perit. Dial. Int. 25 107-131.
91. P.A. Pizzo, K.J. Robichaud, F.A. Gill, et al. (1982) Empiric antibiotics and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72 101-111.
92. W.G. Powderly, G.S. Kobayashi, G.P. Herzig, et al. (1988) Amphotericin B–resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84 826-832.
93. R. Raaijmakers, C. Schroder, L. Monnens, et al. (2007) Fungal peritonitis in children on peritoneal dialysis. Pediatr. Nephrol. 22 288-293.
94. A.C. Reboli, C. Rotstein, P.G. Pappas, et al. (2007) Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356 2472-2482.
95. J.H. Rex, P.G. Pappas, A.W. Karchmer, et al. (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36 1221-1228.
96. J.H. Rex, J.E. Bennett, A.M. Sugar, et al. (1995) Intravascular catheter exchange and duration of candidemia. Clin. Infect. Dis. 21 994-996.
97. A. Rodriguez-Nunez (2001) Incidence and mortality of proven invasive Candida infections in pediatric intensive care patients. Infect. Control. Hosp. Epidemiol. 22 477-478.
98. P. Roig, R. Carrasco, M. Salavert, et al. (1992) Laringitis candidiascia e infeccion por VIH: Descripcion de cuatro casos. Rev. Clin. Esp. 191 261-263.
99. C. Rotstein, E.J. Bow, M. Laverdiere, et al. (1999) Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. Clin. Infect. Dis. 28 331-340.
100. A. Safdar, D.S. Perlin and D. Armstrong (2002) Hematogenous infections due to Candida parapsilosis: Changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn. Microbiol. Infect. Dis. 44 11-16.
101. L. Saiman, E. Ludington, M. Pfaller, et al. (2000) Risk factors for candidemia in neonatal intensive care unit patients: The National Epidemiology of Mycosis Study survey group. Pediatr. Infect. Dis. J. 19 319-324.
102. V. Sanchez, J.A. Vazquez, D. Barth-Jones, et al. (1993) Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am. J. Med. 94 577-582.
103. N.L. Seibel, C. Schwartz, A. Arrieta, et al. (2005) Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49 3317-3324.
104. M.A. Slavin, B. Osborne, R. Adams, et al. (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: A prospective randomized, double-blind study. J. Infect. Dis. 171 1545-1552.
105. J.D. Sobel, C.A. Kauffman, D. McKinsey, et al. (2000) Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo. Clin. Infect. Dis. 30 19-24.
106. J.S. Solomkin, A.B. Flohr, P.G. Quie, et al. (1980) The role of Candida in intraperitoneal infections. Surgery 88 524-530.
107. J.K. Stamos and A.H. Rowley (1995) Candidemia in a pediatric population. Clin. Infect. Dis. 20 571-575.
108. Y.H. Thong and A. Ferrante (1978) Alternative pathway of complement activation by Candida albicans. Aust. N. Z. J. Med. 8 620-622.
109. W.E. Trick, S.K. Fridkin, J.R. Edwards, et al. (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35 627-630.
110. S. Trifilio, S. Singhal, S. Williams, et al. (2007) Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 40 451-456.
111. R.B. Turner, L.G. Donowitz and J.O. Hendley (1985) Consequences of candidemia for pediatric patients. Am. J. Dis. Child. 139 178-180.
112. A.J. Ullman, J.H. Lipton, D.H. Vesole, et al. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356 335-347.
113. J.A. Vazquez and J.D. Sobel (2006) Anidulafungin: A novel echinocandin. Clin. Infect. Dis. 43 215-222.
114. C.C. Villar, H. Kashleva, C.J. Nobile, et al. (2007) Mucosal tissue invasion by Candida albicans is associated with E-cadherin degradation, mediated by transcription factor Rim101p and protease Sap5p. Infect. Immun. 75 2126-2135.
115. M. Vorreith (1968) Mycotic encephalitis. Acta Neuropathol. (Berl.) 11 55-68.
116. T.J. Walsh, P.C. Adamson, N.L. Seibel, et al. (2005) Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49 4536-4545.
117. T.J. Walsh, H. Teppler, G.R. Donowitz, et al. (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351 1391-1402.
118. T.J. Walsh, P. Pappas, D.J. Winston, et al. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346 225-234.
119. T.J. Walsh, J.L. Goodman, P. Pappas, et al. (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob. Agents Chemother. 45 3487-3496.
120. T.J. Walsh, R.W. Finberg, C. Arndt, et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 340 764-771.
121. B.A. Warady, M. Bashir and L.A. Donaldson (2000) Fungal peritonitis in children receiving peritoneal dialysis: A report of the NAPRTCS. Kidney Int. 58 384-389.
122. B.A. Warady, F. Schaefer, M. Holloway, et al. (2000) International Society for Peritoneal Dialysis (ISPD) Advisory Committee on Peritonitis Management in Pediatric Patients: Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit. Dial. Int. 20 610-624.
123. R.M. Ward, F.R. Sattler and A.S. Dalton (1983) Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis. Pediatrics 72 234-238.
124. D.W. Warnock, J.D. Milne and A.W. Fielding (1978) Immunoglobulin classes of human serum antibodies in vaginal candidiasis. Mycopathologia 63 173-175.
125. J.R. Wingard, M.H. White, E. Anaissie, et al. (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. LAmph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31 1155-1163.
126. J.R. Wingard, W.G. Merz, M.G. Rinaldi, et al. (1991) Increase in Candida krusei infections among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325 1274-1277.
127. D.J. Winston, P.H. Chandrasekar, H.M. Lazarus, et al. (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann. Intern. Med. 118 495-503.
128. R.C. Young, J.E. Bennett, G.W. Geelhoed, et al. (1974) Fungemia with compromised host resistance. A study of 70 cases. Ann. Intern. Med. 80 605-612.
129. T.E. Zaoutis, K. Heydon, R. Localio, et al. (2007) Outcomes attributable to neonatal candidiasis. Clin. Infect. Dis. 44 1187-1193.
130. T.E. Zaoutis, S.E. Coffin, J.H. Chu, et al. (2005) Risk factors for mortality in children with candidemia. Pediatr. Infect. Dis. J. 24 736-739.
131. T.E. Zaoutis, E. Foraker, K.L. McGowan, et al. (2005) Antifungal susceptibility of Candida spp. isolated from pediatric patients: A survey of 4 children's hospitals. Diagn. Microbiol. Infect. Dis. 52 295-298.
132. T.E. Zaoutis, H.M. Greves, E. Lautenbach, et al. (2004) Risk factors for disseminated candidiasis in children with candidemia. Pediatr. Infect. Dis. J. 23 635-641.